By randomizing 10,000 adult patients, ARTEMIS will evaluate the effects of a study medicine versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.
Novo Nordisk, in collaboration with the Duke Clinical Research Institute (DCRI), will initiate a global cardiovascular outcomes study called ARTEMIS.
The ARTEMIS study will be conducted globally and is scheduled to begin patient enrollment in mid-2024. This double-blind, randomized trial will follow 10,000 eligible adults for two years. It is a large-scale study to investigate the potential of the study medicine, an IL-6 inhibitor administered once monthly as a subcutaneous injection, to reduce the risk of major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI).
“The ARTEMIS trial builds on the deep history of DCRI executing clinical trials in acute coronary syndrome that became the evidence for clinicians around the world. We are excited about the opportunity to collaborate with Novo Nordisk to support this study with experienced scientific and operational resources to further advance our scientific understanding in this area,” said Adrian Hernandez, MD, MHS, Vice Dean and Executive Director of DCRI and Principal Investigator for ARTEMIS.